Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Share-based Compensation (2021 - 2025)

SAB Biotherapeutics' Share-based Compensation history spans 5 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 370.19% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $5.2 million, up 77.12%, while the annual FY2025 figure was $5.2 million, 77.12% up from the prior year.
  • Share-based Compensation reached $3.2 million in Q4 2025 per SABSW's latest filing, up from $800764.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q4 2025 to a low of $349115.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $865418.0, with a median of $633892.5 recorded in 2022.
  • Peak YoY movement for Share-based Compensation: crashed 70.44% in 2024, then surged 370.19% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $651472.0 in 2021, then decreased by 3.52% to $628539.0 in 2022, then skyrocketed by 262.78% to $2.3 million in 2023, then plummeted by 70.44% to $674135.0 in 2024, then soared by 370.19% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Share-based Compensation are $3.2 million (Q4 2025), $800764.0 (Q3 2025), and $627198.0 (Q2 2025).